Literature DB >> 20627347

Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells.

Joachim Zwilling1, Katja Sliva, Astrid Schwantes, Barbara Schnierle, Gerd Sutter.   

Abstract

Modified vaccinia virus Ankara (MVA) was generated by serial passaging in chicken embryo fibroblasts. During this attenuation, MVA lost the capacity to productively grow in human and most other mammalian cell lines, as well as acquiring a multitude of deletions and mutations in the MVA genome. This means that the precise molecular basis for the MVA host-range restriction is still unknown. The vaccinia virus (VACV) genes F11L and K1L are mutated or truncated in MVA. F11L was previously implicated in VACV-induced cell motility and virion maturation. Here, we demonstrate that the restoration of F11L gene expression in MVA rescued virus-induced cell motility, but had no impact on MVA virion maturation and host-range restriction. Additional insertion of the K1L gene, which restores MVA replication in RK-13 cells, was not sufficient to extend MVA growth capacity to other mammalian cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627347     DOI: 10.1016/j.virol.2010.05.008

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Small rho GTPases and cholesterol biosynthetic pathway intermediates in African swine fever virus infection.

Authors:  Jose I Quetglas; Bruno Hernáez; Inmaculada Galindo; Raquel Muñoz-Moreno; Miguel A Cuesta-Geijo; Covadonga Alonso
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

Review 2.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Modulation of the myxoma virus plaque phenotype by vaccinia virus protein F11.

Authors:  Chad R Irwin; David H Evans
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

4.  Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

Authors:  Sharon Melamed; Linda S Wyatt; Robin J Kastenmayer; Bernard Moss
Journal:  Vaccine       Date:  2013-08-06       Impact factor: 3.641

5.  Protein B5 is required on extracellular enveloped vaccinia virus for repulsion of superinfecting virions.

Authors:  Virginie Doceul; Michael Hollinshead; Adrien Breiman; Kathlyn Laval; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2012-05-23       Impact factor: 3.891

6.  Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.

Authors:  Chad R Irwin; Nicole A Favis; Kate C Agopsowicz; Mary M Hitt; David H Evans
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

7.  A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.

Authors:  Christopher Weber; Sarah M Büchner; Barbara S Schnierle
Journal:  PLoS Negl Trop Dis       Date:  2015-04-23

8.  SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.

Authors:  Ruikang Liu; Jorge D Mendez-Rios; Chen Peng; Wei Xiao; Andrea S Weisberg; Linda S Wyatt; Bernard Moss
Journal:  PLoS Pathog       Date:  2019-05-30       Impact factor: 6.823

Review 9.  The strategic use of novel smallpox vaccines in the post-eradication world.

Authors:  Joseph W Golden; Jay W Hooper
Journal:  Expert Rev Vaccines       Date:  2011-07       Impact factor: 5.683

10.  TRAF2 facilitates vaccinia virus replication by promoting rapid virus entry.

Authors:  Ismar R Haga; Tali Pechenick Jowers; Samantha J Griffiths; Juergen Haas; Philippa M Beard
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.